TEL AVIV, Israel, March 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.
|28th Annual ROTH Conference|
|Date:||Monday, March 14|
|Time:||1:00pm Pacific Time|
|Location:||Ritz Carlton, Laguna Niguel, California|
|Presenter:||David Baker, Chief Commercial Officer|
|Barclays Global Healthcare Conference|
|Date:||Thursday, March 17|
|Time:||10:45am Eastern Time|
|Location:||Loews Miami Beach Hotel, Miami, Florida|
|Presenter:||Dr. Yaron Daniely, President & Chief Executive Officer|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 firstname.lastname@example.org Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 email@example.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 firstname.lastname@example.org